SR9009 Transdermal

SR9009 Transdermal (Liquid Form) – Product Details

• This liquid is offered as 17mg per ml/60ml/1g

Product Information

• CAS Number is stated as 1379686-29-9
• Molar Mass is 479.04 g·mol−1
• It has a Chemical Formula of C23H31ClN4O3S
• IUPAC Name is 3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)-N-pentylpyrrolidine-1-carboxamide

What is SR9009 Transdermal?

Stenabolic (SR-9009) is a special chemical that is a ReV-Erba agonist. That means it’s not a SARM, which is what many people think it is. What makes this compound special is that it can stimulate and turn on the Rev-ErbA, which could lead to more mitochondria. Proteins called REV-ERBs regulate circadian rhythms, which are 24-hour cycles that make up the body’s clock.

Circadian rhythms help the body do many important things. Some of these are how you eat and digest food, when you feel alert and when you feel sleepy, and your body temperature. This means that SR-9009 could lead to more stamina, endurance, and exercise capacity if it can be proven to work.[R]

How Does SR9009 Transdermal Work?

The synthetic compound SR9009 controls the body’s metabolic processes by interacting with a protein called REV-ERB. This interaction is necessary for the compound to exert its effects. It is possible to enter the bloodstream and have an interaction with REV-ERB when it is administered transdermally. However, its efficacy and safety in humans have not been thoroughly researched, so exercising caution is strongly recommended.

In cancer, Sulli et al. demonstrated that activation of REV-ERB proteins using SR9009 and SR9011 agonists led to cancer cell death without affecting normal cell viability. Moreover, SR9009 reduced tumor growth in vivo and showed no toxicity, indicating its potential as a treatment for cancer. [R]

SR9009 Transdermal Research

Multiple animal and cell-based studies have been conducted on SR9009 Transdermal. This research chemical has also been the subject of clinical research. All of these studies have shown that SR9009 Transdermal can’t is a synthetic REV-ERB agonist that can reduce fat-storing cells, increase lean muscle mass, and improve cholesterol levels.

However, in the absence of randomized, large-scale, placebo-controlled trials, the FDA is yet to approve SR9009 Transdermal for human consumption. Therefore, Behemoth Labz sells SR9009 Transdermal for laboratory and research purposes, not for human use.

 SR-9009 and Potential on Fat Mass on diet-induced obese mice

Diet-induced obese mice that were given SR9009 had their fat mass and plasma lipids go down in an animal study. After 12 days of treatment, SR9009 stopped leptin-deficient mice from gaining as much weight as they normally would. [R]

SR-9009 and Potential Effects on Blood Cholesterol

In another animal study, Stenabolic was given to mice that had been changed genetically for eight weeks. The mice were fed a high-cholesterol diet so that their fat would look like people’s. Total cholesterol, triglycerides, and LDL cholesterol all went down after treatment with SR9009, but HDL cholesterol didn’t change. [R]

In a study conducted on genetically modified mice (C57Bl/6 and LDLR deletion mice), it demonstrated that the SR9009 agonist, which targets the REV-ERB receptor, can lower plasma cholesterol levels and downregulate the expression of several genes involved in cholesterol biosynthesis. [R]

SR-9009 and Potential Implications for Endurance

A recent study found that mice administered SR9009 could run longer distances and for longer durations than vehicle-treated mice. This research compound also increased the number of total and active mitochondria. [R]

SR-9009 and Potential to Effect Inflammation

In a study involving rats with ventilator-induced lung injury (VILI), SR9009 treatment greatly diminished VILI-induced lung edema, inflammatory cell infiltration, and the production of the pro-inflammatory cytokine TNF-α (the protein that causes inflammation in response to infection). [R]

SR-9009 and Prostate Cancer

In this study using a cell line, researchers discovered that SR9009 could selectively and dose-dependently kill prostate cancer cells while leaving normal prostate cells unharmed. This indicates that SR9009 has the potential to be an effective prostate cancer treatment. SR9009 was able to inhibit the most aggressive and lethal PCS1 tumors by inhibiting the FOXM1 pathway. In addition, the drug was discovered to activate LXR, resulting in decreased proliferation, cell cycle progression, and migration of prostate cancer cells, while promoting apoptosis. This study provides new insights into the potential of SR9009 as a drug for the treatment of prostate cancer.[R]

SR9009 and Circadian Rhythms

REV-ERBa protein, which are nuclear receptors that control the circadian clock and can be targeted with small molecule ligands. A study conducted with mice shows that synthetic rev erb agonists can change the structure of sleep by making mice wake up during the day. Using EEG recordings, the authors looked into the therapeutic potential of the REV-ERB agonist SR9009 for regulating sleep.

They did this by figuring out how well it worked and when the best time to take it was. They found that giving SR9009 more than once a day doesn’t make it less effective and that giving it once a day for three days doesn’t lead to tolerance. The best time to give SR9009 in terms of how well it works has been found, and there is a 12-hour window in which SR9009 works. The authors say that the REV-ERBs could be used to treat sleep problems with circadian rhythm caused by shift work or jet lag. [R]

Further research and clinical trials would be necessary to determine the safety and efficacy of REV-ERB agonists in human subjects.

SR9009 and Weight Loss

The study was conducted on 20-week-old C57BL/6 mice that had been maintained on a high-fat diet for 14 weeks. The mice continued on the high-fat diet, and twice-daily parenteral solutions (intraperitoneal) of SR9009 were initiated. The mice injected with SR9009 exhibited weight loss of 60% greater than the weight loss of vehicle-treated controls, despite there being no significant difference in food intake between the two groups during the treatment period. [R]

The significant fat loss in mice test subjects treated can also be attributed to the stress of handling and twice-daily parenteral solutions with the mice. Thus further research is suggested to understand its effect on lipid and glucose metabolism

SR9009 and Total Cholesterol

In a similar study above, mice that ate a high-fat diet and were given the REV-ERB agonist SR9009 also saw a significant drop in their total plasma cholesterol levels. In particular, the study found that treatment with SR9009 caused plasma total cholesterol to drop by 47% compared to controls who were given a placebo. This suggests that focusing on the rev erbα could be a possible way to treat dyslipidemia and other disorders in metabolic activity. [R]

More research needs to be done to find out if REV-ERB agonists are safe and effective in humans before they can be used in the clinic.

SR9009 and Small-Cell Lung Cancer

According to a study, the REV-ERB agonist SR9009 can kill both chemosensitive and chemoresistant Small-Cell Lung Cancer (SCLC) cells by inhibiting autophagy via suppression of the autophagy gene Atg5. The study suggests that SR9009 could be a promising therapeutic strategy for treating SCLC. By suppressing autophagy activity through the interaction between REV-ERBα and Atg5, SR9009 exerts cytotoxic effects on SCLC cells.[R]

SR9009 and Skeletal Muscle Growth

The nuclear receptor Rev-erb- plays an essential part in the regulation of a variety of metabolic processes that occur in the liver, including glucose metabolism, adipogenesis, thermogenesis, and the function of mitochondria in skeletal muscle. As was discussed earlier, SR9009 is a compound that activates the ligand-activated nuclear receptor Rev-erb. In addition, it has been shown to have a positive effect on the endurance training of skeletal muscles. The findings indicate that Rev-erb-a could be a potential target for pharmacological interventions that aim to preserve muscle mass. [R]

SR9009 and Improve Muscle Endurance

It was demonstrated in a study that was carried out on mice that activation of Rev-erb- improves the function of muscle mitochondria. The purpose of this study was to determine the effect that pharmacological activation of Rev-erb- has on one’s ability to exercise. This was accomplished by administering the synthetic ligand SR9009 to mice. Notably, in a test of physical endurance, mice given SR9009 ran significantly further and for a longer period of time than mice given a vehicle. [R]

SR9009 Transdermal Side Effects

Taking Stenabolic orally may be unsafe, and there have been no human studies conducted on its use. Certain articles have reported potential side effects of SR9009, including severe headaches and increased water retention.

Note: To support your research further, consider exploring our Transdermal Research Compounds. For additional related compounds, check out 7-Keto DHEA Transdermal and SR9011 Transdermal, which may offer complementary research insights.

Frequently Asked Questions (FAQs)

What is the half-life of SR9009 Transdermal?

The half-life of SR9009 is very short. The half-life of SR9009 is only 4 to 6 hours.

Is SR9009 Transdermal legal?

 The safety and efficacy of SR9009 in humans have not been thoroughly studied, and regulatory agencies such as the FDA have not approved it for human use. In terms of improving exercise performance, animal studies have shown promising results, but it is important to note that these findings may not necessarily apply to humans.

Is SR9009 a Selective Androgen Receptor Modulator?

Although SR9009 is occasionally marketed as a SARM (Selective Androgen Receptor Modulator), it is not a SARM. It is a compound that functions by activating Rev-erb, a protein involved in regulating the circadian rhythm and metabolism of the body.

Where to Buy SR9009 Transdermal for Sale?

BehemothLabz is the best place to buy SR9009 Transdermal online.

We have been around since 2014, supplying the highest-quality research compounds money can buy. All of our products come with a 100% satisfaction guarantee, free and fast shipping, and a money-back guarantee.

SR9009 Transdermal Summary

SR9009 Transdermal is a research chemical that acts as a synthetic rev erb agonist, which regulates circadian rhythms in the body. It can potentially lead to increases in stamina, endurance, and exercise capacity. SR9009 can be administered transdermally and has been shown in multiple animal and cell-based studies to reduce fat mass, increase lean muscle mass, improve cholesterol levels, improve endurance, and decrease inflammation. It has also shown potential in the treatment of prostate cancer. However, the FDA has not yet approved SR9009 for human consumption, and further research and clinical trials are necessary to determine its safety and efficacy in human subjects.

BehemothLabz Disclaimer

Please make sure you go through the Terms and Conditions, and please familiarize yourself with it as it is important.

Please research the scientific uses of this product before making any purchases.

Make note that the packaging and labels of the product may differ from those shown on the website.

Buying the product means you agree with our Terms and Conditions. You can contact our awesome customer service team at support@behemothlabz.com if you are not fully satisfied with the product.

Customer satisfaction is our number one priority!

ATTENTION: All BehemothLabz products are strictly for LABORATORY RESEARCH USE PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Variation	60ml / 17mg per ml / 1g

1st Party COA

3rd Party COA